• Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates americanpharmaceuticalreview
    January 26, 2021
    Merck announced the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates ...
PharmaSources Customer Service